Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi
For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
Little more than a decade ago, the concept of digital twins in life science research may have sounded more like science fiction than a viable model for research and development (R&D).
